These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 2822901)

  • 1. Extinction of mineralocorticoid effects in 19-norprogesterone derivatives: structure-activity relationships.
    Paris J; Botella J; Fournau P; Bonnet P; Thevenot R
    J Pharmacol Exp Ther; 1987 Oct; 243(1):288-91. PubMed ID: 2822901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progestogens with antimineralocorticoid activity.
    Losert W; Casals-Stenzel J; Buse M
    Arzneimittelforschung; 1985; 35(2):459-71. PubMed ID: 4039568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 19-Nor progesterone is a mineralocorticoid agonist.
    Funder JW; Adam WR
    Endocrinology; 1981 Jul; 109(1):313-5. PubMed ID: 6263590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of new 19 nor progesterone derivatives with progestagen, mineralocorticoid and glucocorticoid cytosolic receptors.
    Botella J; Porthe-Nibelle J; Paris J; Lahlou B
    J Pharmacol; 1986; 17(4):699-706. PubMed ID: 3560978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineralocorticoid and hypertensive effects of 19-nor-progesterone.
    Hall CE; Gomez-Sanchez CE; Hungerford S; Gomez-Sanchez EP
    Endocrinology; 1981 Oct; 109(4):1168-75. PubMed ID: 7285865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Affinity of 18,19-dihydroxydeoxycorticosterone and 18-hydroxy-19-nor-deoxycorticosterone to aldosterone receptor and their mineralocorticoid activity.
    Okamoto M; Momoi K; Yamano T; Nakamura M; Odaguchi K; Shimizu T; Okada T; Terasawa T
    Biochem Int; 1983 Dec; 7(6):687-94. PubMed ID: 6237653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships of the molecular structure of aldosterone derivatives with their binding affinity for mineralocorticoid receptor.
    Yamakawa M; Ezumi K; Shiro M; Nakai H; Kamata S; Matsui T; Haga N
    Mol Pharmacol; 1986 Dec; 30(6):585-9. PubMed ID: 3023811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excretion of electrolytes in Brown Norway and Fischer 344 rats: effects of adrenalectomy and of mineralocorticoid and glucocorticoid receptor ligands.
    Marissal-Arvy N; Mormède P
    Exp Physiol; 2004 Nov; 89(6):753-65. PubMed ID: 15364879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal receptor-binding activity of reduced metabolites of aldosterone: evidence for a mineralocorticoid effect outside of the classic aldosterone receptor system.
    Gomez-Sanchez CE; Smith JS; Ferris MW; Gomez-Sanchez EP
    Endocrinology; 1984 Aug; 115(2):712-5. PubMed ID: 6086276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoid like effect of new 18-hydroxy-steroid isolated from urine of hypertensive patients.
    Palem-Vliers M; Fontaine F; Genard P
    Endocrinol Exp; 1976 Mar; 10(1):59-63. PubMed ID: 1083802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The renal action of spirorenone and other 6 beta,7 beta; 15 beta,16 beta-dimethylene-17-spirolactones, a new type of steroidal aldosterone antagonists.
    Casals-Stenzel J; Buse M; Wambach G; Losert W
    Arzneimittelforschung; 1984; 34(3):241-6. PubMed ID: 6329237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-retaining activity of some natural and synthetic 21-deoxysteroids.
    Burton G; Galigniana M; De Lavallaz S; Brachet-Cota AL; Sproviero EM; Ghini AA; Lantos CP; Damasco MC
    Mol Pharmacol; 1995 Mar; 47(3):535-43. PubMed ID: 7700251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 19-nor analogs of adrenal steroids: mineralocorticoid and glucocorticoid receptor activity.
    Wynne KN; Mercer J; Stockigt JR; Funder JW
    Endocrinology; 1980 Nov; 107(5):1278-80. PubMed ID: 6253261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mechanism of mineralocorticoid action of carbenoxolone.
    Armanini D; Karbowiak I; Krozowski Z; Funder JW; Adam WR
    Endocrinology; 1982 Nov; 111(5):1683-6. PubMed ID: 6290195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potassium prorenoate: a new steroidal aldosterone antagonist.
    Hofmann LM; Chinn LJ; Pedrera HA; Krupnick MI; Suleymanov OD
    J Pharmacol Exp Ther; 1975 Aug; 194(2):450-6. PubMed ID: 1151770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mespirenone and other 15,16-methylene-17-spirolactones, a new type of steroidal aldosterone antagonists.
    Losert W; Bittler D; Buse M; Casals-Stenzel J; Haberey M; Laurent H; Nickisch K; Schillinger E; Wiechert R
    Arzneimittelforschung; 1986 Nov; 36(11):1583-600. PubMed ID: 3028435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antinatriuretic and kaliuretic activities of the reduced derivatives of aldosterone.
    Kenyon CJ; Brem AS; McDermott MJ; Deconti GA; Latif SA; Morris DJ
    Endocrinology; 1983 May; 112(5):1852-6. PubMed ID: 6403339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone receptor measurements during changes in dietary sodium.
    Grekin RJ; Sider RS
    Endocrinology; 1981 Jan; 108(1):109-12. PubMed ID: 6450676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative inhibition by hard and soft metal ions of steroid-binding capacity of renal mineralocorticoid receptor cross-linked to the 90-kDa heat-shock protein heterocomplex.
    Galigniana MD; Piwien-Pilipuk G
    Biochem J; 1999 Aug; 341 ( Pt 3)(Pt 3):585-92. PubMed ID: 10417321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.